| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs | Sarah de Crescenzo | 01/31/20 | San Diego |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| BIO Report: More Work Needed to Improve Diversity at Biotech Firms | Sarah de Crescenzo | 01/30/20 | National |
| Agenda and Speakers Announced for Xcelerating Life Sciences San Diego | Editors | 01/29/20 | National |
| Histogen, Timber Pharma Plan Reverse Mergers to Join Public Markets | Sarah de Crescenzo | 01/28/20 | San Diego |
| Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Frank Vinluan | 01/28/20 | Boston |
| BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely | Sarah de Crescenzo | 01/28/20 | Boulder/Denver |
| Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report | Gareth Macdonald | 01/28/20 | National |
| Life Sciences IPOs Target Collective Raise of More Than $600M This Week | Sarah de Crescenzo | 01/27/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
| CEOs of Women’s Health Companies Fight to Open Investment Floodgates | Sarah de Crescenzo | 01/22/20 | San Diego |
| After Ending Cancer Drug Program, Halozyme Predicts Profits in 2020 | Sarah de Crescenzo | 01/21/20 | San Diego |
| Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More | Frank Vinluan | 01/17/20 | National |
| Event Announcement: Xcelerating Life Sciences San Diego | Editors | 01/16/20 | National |
| FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data | Frank Vinluan | 01/14/20 | National |
| Daré Bioscience Inks Deal With Bayer for Non-Hormonal Contraceptive | Sarah de Crescenzo | 01/14/20 | San Diego |
| NeoGenomics Nabs Human Longevity’s Oncology Division for $37M | Melissa Fassbender | 01/13/20 | National |
| Neurocrine, in Second Epilepsy Deal, Pairs With Swiss Biotech Idorsia | Sarah de Crescenzo | 01/11/20 | San Diego |
| Biotech Roundup: Drug Pricing Promises, Bone Disease Data, IPO Plans & More | Sarah de Crescenzo | 01/10/20 | National |
| DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs | Sarah de Crescenzo | 01/09/20 | San Diego |
| Empirico Raises $17M, Inks 3-Year Antisense Collaboration with Ionis | Sarah de Crescenzo | 01/09/20 | San Diego |
| Mirati Adds Execs With Commercial Experience at Spark, Bristol-Myers | Sarah de Crescenzo | 01/08/20 | San Diego |
| Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto | Sarah de Crescenzo | 01/07/20 | San Diego |
| BioIntervene Raises $30M to Move Nerve Pain Drug Into the Clinic | Sarah de Crescenzo | 01/07/20 | San Diego |
| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| After Antitrust Challenges, Illumina and PacBio Throw in Towel on Merger | Sarah de Crescenzo | 01/03/20 | San Diego |
| Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More | Sarah de Crescenzo | 12/20/19 | National |
| Biogen Strikes Alzheimer’s Deal, Paying $45M for Ionis Tau Drug Rights | Sarah de Crescenzo | 12/19/19 | San Diego |
| FTC Challenges PacBio Acquisition, Says Illumina is a “Monopolist” | Sarah de Crescenzo | 12/18/19 | San Diego |
